Delhi HC nod to Natco Pharma for launch of Chlorantraniliprole and its formulations
CTPR technical is formulated into broadspectrum insecticides used across wide range of crops for pest management.
Hyderabad: Natco Pharma Limited has received Order from Hon'ble High Court of Delhi stating that NATCO is allowed to launch Chlorantraniliprole (CTPR) and its formulations, through its non-infringing process.
NATCO is the 1st Company in India to have received its registration approval given by Central Insecticide Board & Registration Committee (CIB&RC) recorded in its Minutes of the 425th Meeting held on January 25th, 2021, for indigenous manufacture of Chlorantraniliprole (CTPR) Technical 93.00% w/w min. under Section 9(3).
CTPR technical is formulated into broadspectrum insecticides used across wide range of crops for pest management.
NATCO estimates the current market size of CTPR containing products in India to be over INR 2000 crores. The Company plans to launch its products very shortly.
Read also: Delhi HC restrains Natco from infringing Novartis API containing Eltrombopag Olamine
Natco Pharma Limited is a vertically integrated and R&D focused pharmaceutical company engaged in developing, manufacturing and marketing of finished dosage formulations ("FDF") and active pharmaceutical ingredients ("APIs"). The company focuses primarily on niche therapeutic areas and complex products. Natco market and distribute its products in over 40 countries.
Natco sells its FDF products in the United States, India, Europe and the rest of the world ("RoW"). In the API segment, the company has capabilities to develop and manufacture products with multi-step synthesis, semi synthetic fusion technologies, high-potency APIs and peptides.
The company has seven manufacturing facilities spread across India with modern research laboratories, capabilities in New Drug Development, etc
Read also: Natco Pharma secures USFDA nod for Trabectedin for Injection
